CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Botulinum toxin Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00773253
NCT00773253Phase 4Completed
CompareCT.gov

Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia.

University of California, San Francisco·interventional·Posted Oct 16, 2008·Updated Mar 23, 2020

In Brief

A Phase 4 clinical trial evaluating Botulinum toxin A for Cervical Dystonia. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to determine how to improve treatment of patients with cervical dystonia who have not been helped with standard Botox injections. This study is for patients with cervical dystonia who have not benefited from treatment with Botox using conventional "single lead electromyographic (EMG) techniques" for injection. The study aim is to see if these patients may have significantly more benefit if their Botox is injected into muscles that have been chosen with a multi-channel EMG mapping study of the neck prior to Botox injection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Dystonia
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 16, 2008
Enrollment StartApr 1, 2008
Primary CompletionOct 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.7 years ago

Interventions

Botulinum toxin Adrug

All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.